Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pyrotinib Treatment”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06001086
What this trial is testing

A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer

Who this might be right for
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 70
Testing effectiveness (Phase 2)UnknownNCT04246502
What this trial is testing

Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Shandong Cancer Hospital and Institute 200
Post-approval studies (Phase 4)Looking for participantsNCT06217185
What this trial is testing

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

Who this might be right for
HER2-positive Breast CancerAdvanced Breast Cancer
Hebei Medical University Fourth Hospital 100
Testing effectiveness (Phase 2)UnknownNCT04293276
What this trial is testing

Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Henan Cancer Hospital 41
Not applicableLooking for participantsNCT05856383
What this trial is testing

Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC

Who this might be right for
HER2-positive Advanced Breast Cancer
Zhejiang Cancer Hospital 100
Testing effectiveness (Phase 2)UnknownNCT04095390
What this trial is testing

A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2-positive Breast Cancer
Jinming Yu 60
Early research (Phase 1)UnknownNCT04315493
What this trial is testing

Effect of Low-fat Diet on the Pharmacokinetics of Pyrotinib in Healthy Participants

Who this might be right for
Healthy Participants
Jiangsu HengRui Medicine Co., Ltd. 16
Testing effectiveness (Phase 2)UnknownNCT04659499
What this trial is testing

Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer

Who this might be right for
Early Breast Cancer
Peking Union Medical College Hospital 261
Testing effectiveness (Phase 2)UnknownNCT04785729
What this trial is testing

Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI Resistance

Who this might be right for
Safety
Sun Yat-sen University 36
Testing effectiveness (Phase 2)UnknownNCT04088110
What this trial is testing

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Who this might be right for
Breast Cancer FemaleHER2-positive Breast CancerHormone Receptor Positive Malignant Neoplasm of Breast+3 more
Fuzhou General Hospital 77
Not applicableNot Yet RecruitingNCT06537674
What this trial is testing

Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer

Who this might be right for
HER2+ Breast Cancer
Jiangsu Famous Medical Technology Co., Ltd. 100
Testing effectiveness (Phase 2)UnknownNCT05255523
What this trial is testing

Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer

Who this might be right for
Advanced Breast Cancer
Fujian Medical University Union Hospital 60
Large-scale testing (Phase 3)Looking for participantsNCT07615751
What this trial is testing

Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 502
Testing effectiveness (Phase 2)UnknownNCT03923179
What this trial is testing

Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer

Who this might be right for
Breast Cancer
Chinese Academy of Medical Sciences 32
Testing effectiveness (Phase 2)UnknownNCT05318339
What this trial is testing

Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Carcinoma, Transitional CellHER-2 Gene Amplification
Chinese Academy of Medical Sciences 30
Testing effectiveness (Phase 2)Looking for participantsNCT06684600
What this trial is testing

Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma
Peking University 35
Testing effectiveness (Phase 2)UnknownNCT05350917
What this trial is testing

Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy

Who this might be right for
HER2-positive or Mutated Advanced Colorectal Cancer
The First Affiliated Hospital of Zhengzhou University 20
Testing effectiveness (Phase 2)UnknownNCT05430347
What this trial is testing

Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 80
Testing effectiveness (Phase 2)Looking for participantsNCT07340398
What this trial is testing

Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer

Who this might be right for
HER2-positive Early Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 200
Testing effectiveness (Phase 2)UnknownNCT04255056
What this trial is testing

Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab

Who this might be right for
Breast Cancer
Sun Yat-sen University 27
Next Page